Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 24 2025
0mins
Source: Newsfilter
Liminatus Pharma's Strategic Move: Liminatus Pharma, a preclinical-stage biopharmaceutical company focused on cancer immunotherapies, has engaged Digital Offering LLC as its exclusive placement agent to explore potential capital raising strategies, including various financing structures compliant with U.S. securities laws.
Focus on Capital Strategy and Innovation: The partnership aims to enhance Liminatus's capital structure while maintaining its commitment to developing transformative cancer therapies, although no financing transaction has been finalized yet.
Analyst Views on LIMN
About LIMN
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
